Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) saw a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 8,979,138 shares, an increase of 1.3% from the January 31st total of 8,860,498 shares. Approximately 5.9% of the shares of the company are short sold. Based on an average daily trading volume, of 479,296 shares, the short-interest ratio is presently 18.7 days.
NYSEAMERICAN:NAVB opened at $0.17 on Friday. Navidea Biopharmaceuticals has a 52 week low of $0.10 and a 52 week high of $0.42.
TRADEMARK VIOLATION WARNING: “Navidea Biopharmaceuticals Inc (NAVB) Short Interest Update” was posted by Zolmax and is the sole property of of Zolmax. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://zolmax.com/investing/navidea-biopharmaceuticals-inc-navb-short-interest-update-2/2928408.html.
About Navidea Biopharmaceuticals
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.
See Also: Limitations of the P/E Growth ratio
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.